134 related articles for article (PubMed ID: 2523485)
1. 9,11-Epoxy-9-homo-14-thiaprost-5-enoic acid derivatives: potent thromboxane A2 antagonists.
Hall SE; Han WC; Harris DN; Hedberg A; Ogletree ML
J Med Chem; 1989 May; 32(5):974-84. PubMed ID: 2523485
[TBL] [Abstract][Full Text] [Related]
2. 9,11-epoxy-9-homoprosta-5-enoic acid analogues as thromboxane A2 receptor antagonists.
Das J; Hall SE; Nakane M; Haslanger MF; Reid JA; Garber D; Truc VC; Harris DN; Hedberg A; Ogletree ML
J Med Chem; 1990 Jun; 33(6):1741-8. PubMed ID: 2140414
[TBL] [Abstract][Full Text] [Related]
3. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
Naka M; Mais DE; Morinelli TA; Hamanaka N; Oatis JE; Halushka PV
J Pharmacol Exp Ther; 1992 Aug; 262(2):632-7. PubMed ID: 1386885
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
Harris DN; Michel IM; Goldenberg HJ; Hartl KS; Allen GT; Steinbacher TE; Schumacher WA; Han WC; Hall SE; Floyd DM
J Pharmacol Exp Ther; 1992 Apr; 261(1):131-7. PubMed ID: 1532833
[TBL] [Abstract][Full Text] [Related]
5. 7-Oxabicyclo[2.2.1]heptyl carboxylic acids as thromboxane A2 antagonists: aza omega-chain analogues.
Nakane M; Reid JA; Han WC; Das J; Truc VC; Haslanger MF; Garber D; Harris DN; Hedberg A; Ogletree ML
J Med Chem; 1990 Sep; 33(9):2465-76. PubMed ID: 2391688
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist.
Ogletree ML; Harris DN; Greenberg R; Haslanger MF; Nakane M
J Pharmacol Exp Ther; 1985 Aug; 234(2):435-41. PubMed ID: 3926986
[TBL] [Abstract][Full Text] [Related]
7. Labeling of human platelet plasma membrane thromboxane A2/prostaglandin H2 receptors using SQB, a novel biotinylated receptor probe.
Komiotis D; Wencel-Drake JD; Dieter JP; Lim CT; Le Breton GC
Biochem Pharmacol; 1996 Sep; 52(5):763-70. PubMed ID: 8765474
[TBL] [Abstract][Full Text] [Related]
8. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
Hanasaki K; Arita H
Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a thromboxane A2/prostaglandin H2 receptor in guinea pig lung membranes using a radioiodinated thromboxane mimetic.
Saussy DL; Mais DE; Dubé GP; Magee DE; Brune KA; Kurtz WL; Williams CM
Mol Pharmacol; 1991 Jan; 39(1):72-8. PubMed ID: 1824791
[TBL] [Abstract][Full Text] [Related]
11. The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets.
Mayeux PR; Morton HE; Gillard J; Lord A; Morinelli TA; Boehm A; Mais DE; Halushka PV
Biochem Biophys Res Commun; 1988 Dec; 157(2):733-9. PubMed ID: 2974286
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN
J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108
[TBL] [Abstract][Full Text] [Related]
13. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
[TBL] [Abstract][Full Text] [Related]
14. Platelet and vascular smooth muscle thromboxane A2/prostaglandin H2 receptors.
Halushka PV; Mais DE; Saussy DL
Fed Proc; 1987 Jan; 46(1):149-53. PubMed ID: 2948839
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
16. Non-prostanoid thromboxane A2 receptor antagonists with a dibenzoxepin ring system. 2.
Ohshima E; Takami H; Sato H; Mohri S; Obase H; Miki I; Ishii A; Shirakura S; Karasawa A; Kubo K
J Med Chem; 1992 Sep; 35(18):3402-13. PubMed ID: 1388208
[TBL] [Abstract][Full Text] [Related]
17. 9,11-Epoxy-9-homo-14-oxaprosta-5-enoic acid derivatives. Novel inhibitors of fatty acid cyclooxygenase.
Hall SE; Han WC; Haslanger MF; Harris DN; Ogletree ML
J Med Chem; 1986 Nov; 29(11):2335-47. PubMed ID: 3097316
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives.
Fukumoto S; Shiraishi M; Terashita Z; Ashida Y; Inada Y
J Med Chem; 1992 Jun; 35(12):2202-9. PubMed ID: 1535377
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
Furci L; Fitzgerald DJ; Fitzgerald GA
J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
